Ozurdex recommended for treating macular oedema
The National Institute for Health and Clinical Excellence (NICE) has recommended Ozurdex for the treatment of macular oedema caused by central retinal vein occlusion (CRVO).
The National Institute for Health and Clinical Excellence (NICE) has recommended Ozurdex for the treatment of macular oedema caused by central retinal vein occlusion (CRVO).
The dexamethasone 0.7 mg biodegradable intravitreal implant can be used as an alternative treatment if laser photocoagulation is not effective. Findings of a recent study demonstrated a clinically significant improvement in vision in 30% of patients and 80% of patients demonstrated an improvement or no deterioration of vision over 6 months.
Mr Ian Pearce, consultant ophthalmologist and clinical expert representative of the Royal College of Ophthalmologists said: "The availability of a licensed, effective and now NICE recommended treatment is a significant step forward for management of RVO patients in England and Wales.
Mr Douglas D. Ingram, executive vice president, president, Allergan, Europe, Africa and Middle East, said: "We look forward to working with retinal specialists, hospitals and commissioning groups in the UK to support the National Health Service in rapidly adopting this cost effective solution to maximize patient benefits and to minimize premature vision loss as a result of RVO."
